FDA approves Pfizer's avetin biosimilar drug bevadoford for treatment of five cancers
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, Pfizerannounced in theof thehttp:// (NYSE: PFE) that the u.SFoodDrug(http://Regulatory Authority http://
(http://has approved the avastin ®, bevacizumab biosimilar drug bevanoviaanda (ZIEVRAB, bevacizumab-bvzr) for the treatment of five types of cancerthese five types of cancer include: metastatic colorectal cancer, non-reprecented localized or metastatic non-squamous non-small cell lung cancer (NSCLC), recurrent malignant glioma, metastatic renal cell carcinoma (RCC) and persistent, recurrent or metastatic cervical cancerAbout ZIVACEV (bevacizumab-bvzr)ZIRABEV is a monoclonal antibody biosimilar of theProduct(http://of anvitin, which inhibits the production (angiogenesis) of new blood cells by specifically identifying and binding vascular endothelial growth factors (VEGF) ZiRABEV has been studied in nearly 400 patients to date as part of the REFLECTIONS Clinical Trial (http:// program The FDA's approval decision is based on a review of the comprehensive packet The data confirm the biological similarity between ZIRABEV and the reference products These data include the results obtained from the REFLECTIONS B7391003 Clinical Comparative Study this study confirmed the clinical equivalence of ZIRABEV and reference products in patients with advanced non-squamous cell lung cancer, and found no clinically significant differences between the two
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
